The relationship between antidepressant and analgesic responses: Findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder

David A Fishbain, Michael J. Detke, Joachim Wernicke, Amy S. Chappell, Daniel K. Kajdasz

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: Debate continues regarding whether onset of analgesia is faster than antidepressant effect in antidepressants with both properties. Duloxetine hydrochloride (from here on referred to as duloxetine) is effective in both major depressive disorder and diabetic peripheral neuropathic pain. This post-hoc analysis of six placebo-controlled duloxetine trials in patients with major depressive disorder was designed to compare onset of antidepressant activity to pain relief. Research design and methods: Duloxetine was administered at 40-120 mg/day versus placebo for up to 9 weeks in outpatient clinic settings. The primary depression measure was the HAMD17 and pain severity was measured using visual analog scale (VAS) measuring overall pain, headache, back and shoulder pain, and pain while awake. The time course of improvement was profiled using repeated measures modeling and Kaplan-Meier product limit estimation. Results: In all but one case, significant reductions in HAMD17 and VAS scores were seen within 2 weeks of treatment. Median time to VAS response was consistently shorter across all VAS measures than that to HAMD17 response in both placebo- and duloxetine-treated patients with at least modest levels of pain at study entry. Regression analyses consistently demonstrated little association between analgesic and antidepressant responses. Limitations of these findings include that the studies used in these analyses did not require the patients to enroll with any specific level of pain. Moreover, the type of pain exhibiting at presentation was not routinely identified; therefore, the impact of different pain types on these findings is unknown. Conclusions: Duloxetine's analgesic effect is independent of the drug's antidepressant effect. Additionally, faster onset of the analgesic effect appears to be a populationspecific phenomenon that is unmodified in the presence of active agents.

Original languageEnglish
Pages (from-to)3105-3115
Number of pages11
JournalCurrent Medical Research and Opinion
Volume24
Issue number11
DOIs
StatePublished - Dec 1 2008

Fingerprint

Major Depressive Disorder
Antidepressive Agents
Analgesics
Placebos
Pain
Visual Analog Scale
Shoulder Pain
Duloxetine Hydrochloride
Neuralgia
Back Pain
Ambulatory Care Facilities
Analgesia
Headache
Research Design
Regression Analysis
Depression

Keywords

  • Analgesia
  • Antidepressant
  • Duloxetine hydrochloride
  • HAMD
  • Serotonin- norepinephrine reuptake inhibitor
  • Visual analog scale

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The relationship between antidepressant and analgesic responses : Findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder. / Fishbain, David A; Detke, Michael J.; Wernicke, Joachim; Chappell, Amy S.; Kajdasz, Daniel K.

In: Current Medical Research and Opinion, Vol. 24, No. 11, 01.12.2008, p. 3105-3115.

Research output: Contribution to journalArticle

@article{d1f08381e9984806a7d3d2217095d4d0,
title = "The relationship between antidepressant and analgesic responses: Findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder",
abstract = "Objective: Debate continues regarding whether onset of analgesia is faster than antidepressant effect in antidepressants with both properties. Duloxetine hydrochloride (from here on referred to as duloxetine) is effective in both major depressive disorder and diabetic peripheral neuropathic pain. This post-hoc analysis of six placebo-controlled duloxetine trials in patients with major depressive disorder was designed to compare onset of antidepressant activity to pain relief. Research design and methods: Duloxetine was administered at 40-120 mg/day versus placebo for up to 9 weeks in outpatient clinic settings. The primary depression measure was the HAMD17 and pain severity was measured using visual analog scale (VAS) measuring overall pain, headache, back and shoulder pain, and pain while awake. The time course of improvement was profiled using repeated measures modeling and Kaplan-Meier product limit estimation. Results: In all but one case, significant reductions in HAMD17 and VAS scores were seen within 2 weeks of treatment. Median time to VAS response was consistently shorter across all VAS measures than that to HAMD17 response in both placebo- and duloxetine-treated patients with at least modest levels of pain at study entry. Regression analyses consistently demonstrated little association between analgesic and antidepressant responses. Limitations of these findings include that the studies used in these analyses did not require the patients to enroll with any specific level of pain. Moreover, the type of pain exhibiting at presentation was not routinely identified; therefore, the impact of different pain types on these findings is unknown. Conclusions: Duloxetine's analgesic effect is independent of the drug's antidepressant effect. Additionally, faster onset of the analgesic effect appears to be a populationspecific phenomenon that is unmodified in the presence of active agents.",
keywords = "Analgesia, Antidepressant, Duloxetine hydrochloride, HAMD, Serotonin- norepinephrine reuptake inhibitor, Visual analog scale",
author = "Fishbain, {David A} and Detke, {Michael J.} and Joachim Wernicke and Chappell, {Amy S.} and Kajdasz, {Daniel K.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1185/03007990802429627",
language = "English",
volume = "24",
pages = "3105--3115",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - The relationship between antidepressant and analgesic responses

T2 - Findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder

AU - Fishbain, David A

AU - Detke, Michael J.

AU - Wernicke, Joachim

AU - Chappell, Amy S.

AU - Kajdasz, Daniel K.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Objective: Debate continues regarding whether onset of analgesia is faster than antidepressant effect in antidepressants with both properties. Duloxetine hydrochloride (from here on referred to as duloxetine) is effective in both major depressive disorder and diabetic peripheral neuropathic pain. This post-hoc analysis of six placebo-controlled duloxetine trials in patients with major depressive disorder was designed to compare onset of antidepressant activity to pain relief. Research design and methods: Duloxetine was administered at 40-120 mg/day versus placebo for up to 9 weeks in outpatient clinic settings. The primary depression measure was the HAMD17 and pain severity was measured using visual analog scale (VAS) measuring overall pain, headache, back and shoulder pain, and pain while awake. The time course of improvement was profiled using repeated measures modeling and Kaplan-Meier product limit estimation. Results: In all but one case, significant reductions in HAMD17 and VAS scores were seen within 2 weeks of treatment. Median time to VAS response was consistently shorter across all VAS measures than that to HAMD17 response in both placebo- and duloxetine-treated patients with at least modest levels of pain at study entry. Regression analyses consistently demonstrated little association between analgesic and antidepressant responses. Limitations of these findings include that the studies used in these analyses did not require the patients to enroll with any specific level of pain. Moreover, the type of pain exhibiting at presentation was not routinely identified; therefore, the impact of different pain types on these findings is unknown. Conclusions: Duloxetine's analgesic effect is independent of the drug's antidepressant effect. Additionally, faster onset of the analgesic effect appears to be a populationspecific phenomenon that is unmodified in the presence of active agents.

AB - Objective: Debate continues regarding whether onset of analgesia is faster than antidepressant effect in antidepressants with both properties. Duloxetine hydrochloride (from here on referred to as duloxetine) is effective in both major depressive disorder and diabetic peripheral neuropathic pain. This post-hoc analysis of six placebo-controlled duloxetine trials in patients with major depressive disorder was designed to compare onset of antidepressant activity to pain relief. Research design and methods: Duloxetine was administered at 40-120 mg/day versus placebo for up to 9 weeks in outpatient clinic settings. The primary depression measure was the HAMD17 and pain severity was measured using visual analog scale (VAS) measuring overall pain, headache, back and shoulder pain, and pain while awake. The time course of improvement was profiled using repeated measures modeling and Kaplan-Meier product limit estimation. Results: In all but one case, significant reductions in HAMD17 and VAS scores were seen within 2 weeks of treatment. Median time to VAS response was consistently shorter across all VAS measures than that to HAMD17 response in both placebo- and duloxetine-treated patients with at least modest levels of pain at study entry. Regression analyses consistently demonstrated little association between analgesic and antidepressant responses. Limitations of these findings include that the studies used in these analyses did not require the patients to enroll with any specific level of pain. Moreover, the type of pain exhibiting at presentation was not routinely identified; therefore, the impact of different pain types on these findings is unknown. Conclusions: Duloxetine's analgesic effect is independent of the drug's antidepressant effect. Additionally, faster onset of the analgesic effect appears to be a populationspecific phenomenon that is unmodified in the presence of active agents.

KW - Analgesia

KW - Antidepressant

KW - Duloxetine hydrochloride

KW - HAMD

KW - Serotonin- norepinephrine reuptake inhibitor

KW - Visual analog scale

UR - http://www.scopus.com/inward/record.url?scp=67649394311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649394311&partnerID=8YFLogxK

U2 - 10.1185/03007990802429627

DO - 10.1185/03007990802429627

M3 - Article

C2 - 18828958

AN - SCOPUS:67649394311

VL - 24

SP - 3105

EP - 3115

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 11

ER -